Landmark Trial: Drug Treatment Allows Children With Multiple Food Allergies to Safely Eat Full Servings

For millions of families, a child's food allergy transforms the daily routine into an exercise in relentless vigilance. A birthday party, a school cafeteria, or a restaurant kitchen cross-contamination can instantly trigger a life-threatening anaphylactic reaction. Traditionally, the only reliable defense has been strict, uncompromising avoidance. But a landmark clinical trial has just demonstrated that a targeted biologic drug can do more than just provide a safety net—it can allow children with multiple severe food allergies to safely consume full servings of the very foods that once threatened their lives.[1]

The findings, published in July 2026 in the journal JAMA Pediatrics, represent the highly anticipated second stage of the nationwide OUtMATCH clinical trial. Led by researchers at Stanford Medicine and Johns Hopkins Children's Center, the study investigated the efficacy of omalizumab, an injectable asthma medication sold under the brand name Xolair. The results revealed that after a year of treatment, more than a third of the children receiving the drug could safely eat normal, 2,000-milligram portions of their trigger foods, including peanuts, dairy, and eggs.[1][5]

The scale of the food allergy crisis makes these results particularly significant. Approximately 8 percent of children in the United States suffer from food allergies, and roughly 40 percent of those children are allergic to more than one specific food. Managing a single allergy is difficult; managing multiple allergies often requires eliminating entire categories of common ingredients, leading to nutritional anxiety and a heavy psychological burden on both the child and their parents.

Omalizumab works by intervening directly in the body's allergic cascade. It is a monoclonal antibody designed to seek out and bind to Immunoglobulin E (IgE)—the specific antibodies that the immune system produces when it mistakenly identifies a harmless food protein as a dangerous invader. By essentially "mopping up" these IgE antibodies before they can attach to immune cells, the drug prevents the release of histamine and other inflammatory chemicals that cause allergic reactions.[2]

The medical community has long understood the potential of this mechanism. Omalizumab was first approved by the U.S. Food and Drug Administration in 2003 as a preventive treatment for allergic asthma. In February 2024, based on the first stage of the OUtMATCH trial, the FDA expanded that approval, authorizing the drug to protect adults and children as young as one year old from severe reactions caused by the accidental ingestion of small amounts of food allergens.[2][3]

However, the 2024 approval came with a strict caveat: patients were explicitly instructed to continue avoiding their trigger foods. The medication was intended solely as a chemical safety net against hidden traces of allergens, not as a license to change their diets. The second stage of the OUtMATCH trial sought to push that boundary, asking whether the drug could raise a patient's tolerance threshold high enough to allow for regular, intentional consumption.[2][5]

The trial enrolled 117 participants, with a median age of seven years old. Every child in the study had a confirmed peanut allergy, alongside allergies to at least two other common foods, such as milk, eggs, wheat, or tree nuts. The researchers set a rigorous benchmark for success: by the end of the year-long trial, a participant had to successfully consume a full 2,000-milligram serving of protein from three different allergenic foods without experiencing a dangerous reaction.[1][4]

The study divided the children into different treatment pathways to compare the effectiveness of omalizumab alone against a combined approach. One group received only the omalizumab injections. The other group received the injections alongside multi-allergen oral immunotherapy (OIT)—a traditional treatment method where patients consume gradually increasing micro-doses of their allergens to slowly build up the immune system's natural tolerance.[1][4]

The results of the head-to-head comparison were striking, and somewhat counterintuitive. In the group receiving omalizumab alone, 36 percent of the children successfully met the rigorous threshold, safely eating full servings of all three of their trigger foods. They were able to consume the equivalent of a standard peanut butter sandwich or a glass of milk without incident, a milestone that would have been unthinkable prior to the treatment.[1]

Conversely, the group receiving the combined therapy—omalizumab plus oral immunotherapy—fared significantly worse. Only 19 percent of the children in this cohort achieved the same level of tolerance. The researchers noted that this discrepancy was not because the combined therapy was inherently less effective at a biological level, but because the traditional immunotherapy component was simply too difficult for the patients to tolerate.[1]

Oral immunotherapy is notoriously grueling. The daily ingestion of allergens frequently causes gastrointestinal distress, mouth itching, and systemic side effects. In the OUtMATCH trial, the side effects associated with the OIT component caused a high number of participants to drop out of the study prematurely. The omalizumab-only group, free from the daily burden of ingesting allergens, experienced a much higher completion rate.[1][5]

The data suggests that for many families, a standalone biologic injection offers a safer, more tolerable, and ultimately more successful path to food tolerance than the grueling regimen of traditional exposure therapy. By bypassing the gastrointestinal distress of oral immunotherapy, the injectable biologic allowed a significantly higher percentage of children to reach the finish line of the trial.[1]

Despite the breakthrough, researchers are careful to highlight the treatment's limitations. Omalizumab is not a permanent cure. The drug suppresses the allergic response only as long as it remains in the patient's system; if the injections stop, the IgE antibodies will eventually rebound, and the severe allergies will return. Furthermore, the treatment did not work for everyone, as nearly two-thirds of the monotherapy group did not reach the full 2,000-milligram tolerance threshold.[2]

Scientists are still working to understand why some children respond so robustly to the medication while others experience only marginal improvements. Future research will likely focus on identifying biomarkers that can predict a patient's response to the drug, allowing pediatricians to better target the therapy to those who will benefit the most.[5]

For the medical community, the OUtMATCH results represent a fundamental paradigm shift in how food allergies are managed. Pediatric allergists can now begin to tailor treatments to a family's specific goals. For some, the objective will remain simple protection against accidental exposure. But for others, this targeted biologic therapy offers a realistic pathway to reintroducing forbidden foods, lifting the heavy veil of anxiety, and allowing children to finally eat without fear.[5]